Chart of the month

by

CCL Fund

Castle Creek Lifescience Partners' CCL Fund has considerably outperformed both the NASDAQ and the Absolute Return Tech index by using

its expertise to make event-driven long and short investments in public biotechnology companies.

The fund has a correlation to the AMEX Biotech Index of 0.45, but maintains significantly less downside deviation and has a net return of 665% since inception, in comparison to 183% for the BTK over the same period. Looking poised to grow further, the fund - managed by Dr. Nathan Fischel out of Beverly Hills - recently saw

its assets